Halozyme CEO sees blockbuster potential in its cancer drug

Halozyme CEO sees blockbuster potential in its cancer drug

NEW YORK (Reuters) – Halozyme Therapeutics Inc believes it has a multibillion-dollar cancer drug on its hands. The drug, PEGPH20, being tested against pancreatic cancer, has the potential to help treat several other types of solid tumor cancers, its

9
Like
Save

Comments

Write a comment

*